Integral Diagnostics Ltd
IDX: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|d#T%<PB | LOCK|Bx | LOCK|dSxptMQ |
Integral Diagnostics Earnings: Shares Undervalued With Margins Expanding to Plan
Integral's interim 2026 underlying revenue grew 7% while operating EBITDA margin rose a strong 130 basis points to 21% on a pro forma basis. They kept full-year operating EBITDA margin guidance of 21%, implying a slight second-half uplift on normal sales seasonality and as cost savings annualize.
